Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 26;8(1):e12360.
doi: 10.1002/trc2.12360. eCollection 2022.

Health economic modeling for Alzheimer's disease: Expert perspectives

Filipa Landeiro  1 , Jasmine Morton  1 , Anders Gustavsson  2   3 , Michele Potashman  4 , Pascal Lecomte  5 , Mark Belger  6 , Robin Thompson  7 , Emilse Roncancio-Diaz  8 , Gurleen Jhuti  9 , Christopher Butler  10 , Linus Jönsson  2   11 , Ron Handels  2   12 , Alastair M Gray  1 ; ROADMAP study
Affiliations

Health economic modeling for Alzheimer's disease: Expert perspectives

Filipa Landeiro et al. Alzheimers Dement (N Y). .

Abstract

The successful development of an economic model for the evaluation of future Alzheimer's disease (AD) interventions is critical to accurately inform policy makers and payers. As our understanding of AD expands, this becomes an increasingly complex and challenging goal. Advances in diagnostic techniques for AD and the prospect of disease-modifying treatments raise an urgent need to define specifications for future economic models and to ensure that the necessary data to populate them are available. This Perspective article provides expert opinions from health economists and governmental agency representatives on how future economic models for AD might be structured, validated, and reported. We aim to stimulate much-needed discussion about the detailed specification of future health economic models for AD.

Keywords: Alzheimer's disease; costs; dementia; disease‐modifying treatment; economic models; model structure; pre‐dementia; quality of life; quality‐adjusted life years.

PubMed Disclaimer

Conflict of interest statement

Filipa Landeiro has been funded by a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). Jasmine Morton: none exist. Anders Gustavsson is a partner of Quantify Research, providing consultancy services to pharmaceutical companies and other private and public organizations and institutions. AG's contribution to ROADMAP was on behalf of Roche Pharmaceuticals. Michele Potashman is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and health care–related companies. Pascal Lecomte is employed by, owns stock in, and has stock options in Novartis Pharma AG. Mark Belger is a full‐time employee and shareholder of Eli Lilly and Company. Robin Thompson is an employee of Biogen and owns stock in Biogen. Emilse Roncancio‐Diaz is employed by GE Healthcare. Gurleen Jhuti is employed by F. Hoffmann‐La Roche Ltd. Christopher Butler: none exist. Linus Jönsson is employed by H. Lundbeck A/S. Ron Handels has received grants from ROADMAP (Innovative Medicines Initiative 2 Joint Undertaking 2016‐2018); consulting fees from Piramal, Roche, and Eisai; grants from Horizon 2020, JPND Joint Programming Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organizations and private–public collaborations (ZonMw Netherlands; Alzheimer Netherlands; Dutch Flutemetamol Study; Alzheimer Research UK; Swedish National study on Aging and Care; European Brain Council). Alastair M. Gray has received a grant from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (ROADMAP). A.M.G. is partially supported by the National Institute for Health Research Biomedical Research Centre at the University of Oxford (grant number NIHR‐BRC‐1215‐20008). Author disclosures are available in the supporting information.

References

    1. Gustavsson A, Pemberton‐Ross P, Gomez Montero M, Hashim M, & Thompson R. Challenges in demonstrating the value of disease‐modifying therapies for alzheimer's disease. Expert Rev Pharmacoeconomics Outcomes Res. 2020;20(6):563–570. - PubMed
    1. Nguyen K‐H, Comans TA, & Green C. Where are we at with model‐based economic evaluations of interventions for dementia? a systematic review and quality assessment. Int Psychogeriatr. 2018;30(11):1593–1605. - PubMed
    1. Hernandez L, Ozen A, DosSantos R, & Getsios D. Systematic review of model‐based economic evaluations of treatments for Alzheimer's disease. PharmacoEconomics. 2016;34(7):681–707. - PubMed
    1. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost‐effectiveness analysis. PharmacoEconomics. 2007;25(9):735–750. - PubMed
    1. Gustavsson A, Green C, Jones RW, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. Alzheimers Dement. 2017;13(3):312–321. - PubMed

LinkOut - more resources